GC Biopharma/Novel Pharma's Sanfilippo Syndrome Treatment Obtains FDA IND Clearance

GC Biopharma (006280. KS) and Novel Pharma have announced that the U.S. FDA has cleared the investigational new drug (IND) application for their jointly developed MPSIIIA (Sanfilippo Syndrome Type A) treatment, GC1130A....

Related Keywords

United States ,Japan ,South Korea ,Seoul ,Soult Ukpyolsi ,Heparann Sulfatase ,Sohee Kim ,Pharma Sanfilippo ,Rachel Kim ,Yelin Jun ,Gc Biopharma Corp ,Green Cross Corporation ,Novel Pharma Inc ,Novel Pharma ,Sanfilippo Syndrome Type ,Orphan Drug Designation ,Rare Pediatric Disease Designation ,Syndrome Type ,